Page 6 - Deepak Bhatt News Today

An experimental implant now under development could serve as a temporary monitor and pacemaker for ailing heart patients -- then dissolve away when it's no longer needed.

FRIDAY, July 7, 2023 (HealthDay News) -- An experimental implant now under development could serve as a temporary monitor and pacemaker for ailing heart patients -- then dissolve away when

Pegozafermin was associated with improvements in fibrosis and could contribute to a resolution of NASH, according to the results of the phase 2b ENLIVEN trial.

Researchers say an artificial intelligence program may help detect retinopathy of prematurity, the leading cause of childhood blindness, in infants

Data suggest that catheter-directed thrombolysis is associated with reduced risk for bleeding and death, compared with systemic thrombolysis.

An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

Ahead of the May 27, 2023 PDUFA date, the HCPLive Cardiology editorial team spoke to a group of cardiologists to capture their perspective of the potential role of sotagliflozin.

An analysis of cost-effectiveness using data from SOLOIST-WHF provides insight into the varying cost-effectiveness of the agent as a treatment for worsening heart failure.